Alzheimer’s disease: An Updated Overview of Its Genetics
Alzheimer’s disease (AD) is a neurodegenerative disorder and represents the most common form of dementia. At present, an estimated 50% of million people worldwide suffer from some form of dementia. AD is characterized by chronic and acquired memory impairment and
APOE ε4’s impact on response to amyloid therapies in early symptomatic Alzheimer’s disease: Analyses from multiple clinical trials
In Alzheimer’s disease, the accumulation and aggregation of amyloid beta (Aβ) peptide into extracellular amyloid plaques is an early event that precedes neurodegeneration and functional and cognitive impairment. Genetic variants
Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s disease and MCI: A Review
Alzheimer’s disease (AD) is a progressive, multifactorial, neurodegenerative disease generally characterized by personality changes, memory loss, and a decline in overall cognitive function. The significant genetic risk factor for AD is the apolipoprotein E, epsilon 4 allele (ApoE4), and the inheritance of one or two copies
Misfolded GBA/β-glucocerebrosidase impairs ER-quality control by chaperone-mediated autophagy in Parkinson disease.
Inhibition of chaperone-mediated autophagy (CMA), a selective type of lysosomal degradation for intracellular proteins, may contribute to pathogenesis in neurodegenerative diseases including Parkinson disease (PD). Pathogenic variants